Successful treatment by adding thalidomide to glucantime in a case of refractory anthroponotic mucocutaneous leishmaniasis

Publication date: Available online 27 August 2019Source: International Journal for Parasitology: Drugs and Drug ResistanceAuthor(s): Vahid Mashayekhi Goyonlo, Sadegh Vahabi-Amlashi, Faezeh TaghaviAbstractMucosal leishmaniasis (ML) is mostly associated with Leishmania braziliensis; however, a few cases of Leishmania tropica induced mucocutaneous leishmaniasis have been reported. The standard treatment for leishmaniasis is pentavalent antimonials, but several other drugs for resistant cases have been proposed including amphotericin and miltefosine. Here we present a case of multiple treatment resistant mucocutaneous leishmaniasis with nasal involvement caused by L. tropica; cure was not achieved by multiple treatments and was eventually improved by adding thalidomide to Meglumine Antimoniate (Glucantime). To the best of our knowledge use of thalidomide in humans for leishmaniasis treatment is reported here for the first time.
Source: International Journal for Parasitology: Drugs and Drug Resistance - Category: Parasitology Source Type: research